Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedNov 18, 2025
DataAggregated Company Financials
Companies176
  • 7D1.6%
  • 3M0.6%
  • 1Y1.1%
  • YTD-5.3%

In the last week, the Pharma industry is up 1.6%, with Sun Pharmaceutical Industries up 2.5%. Meanwhile, Cohance Lifesciences actually underperformed within the industry, shrinking 14% in the last week. Overall in the last year, the industry is flat. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025₹20.6t₹4.2t₹611.4b30.1x33.7x4.9x
Thu, 16 Oct 2025₹20.1t₹4.1t₹589.5b30x34.1x4.9x
Sat, 13 Sep 2025₹20.6t₹4.1t₹589.1b31.5x35x5.1x
Mon, 11 Aug 2025₹19.8t₹4.1t₹592.7b32.4x33.4x4.9x
Wed, 09 Jul 2025₹20.4t₹4.0t₹594.1b33.4x34.3x5.1x
Fri, 06 Jun 2025₹20.1t₹4.0t₹595.3b32.5x33.8x5.1x
Sun, 04 May 2025₹19.6t₹3.9t₹563.0b29.4x34.8x5x
Tue, 01 Apr 2025₹19.4t₹3.9t₹559.4b29.7x34.7x5x
Thu, 27 Feb 2025₹18.5t₹3.9t₹561.5b27.3x32.9x4.7x
Sat, 25 Jan 2025₹19.9t₹3.8t₹527.3b31.6x37.8x5.2x
Mon, 23 Dec 2024₹20.7t₹3.8t₹526.7b33.6x39.3x5.4x
Wed, 20 Nov 2024₹20.1t₹3.8t₹526.2b31.7x38.3x5.3x
Fri, 18 Oct 2024₹21.4t₹3.7t₹492.6b40.8x43.5x5.7x
Sun, 15 Sep 2024₹21.7t₹3.7t₹492.6b42.8x44.1x5.8x
Tue, 13 Aug 2024₹20.4t₹3.8t₹486.1b36.5x41.9x5.4x
Thu, 11 Jul 2024₹18.7t₹3.6t₹449.9b34.8x41.5x5.2x
Sat, 08 Jun 2024₹17.4t₹3.6t₹450.7b32.7x38.6x4.9x
Mon, 06 May 2024₹17.1t₹3.5t₹418.8b34.1x40.9x4.9x
Wed, 03 Apr 2024₹17.2t₹3.5t₹418.9b33.1x41.1x5x
Fri, 01 Mar 2024₹17.0t₹3.5t₹418.7b33.2x40.6x4.9x
Sun, 28 Jan 2024₹15.8t₹3.4t₹396.1b34.6x39.8x4.7x
Tue, 26 Dec 2023₹14.6t₹3.4t₹395.2b32.2x37x4.3x
Thu, 23 Nov 2023₹14.1t₹3.4t₹395.1b30.8x35.8x4.2x
Sat, 21 Oct 2023₹13.1t₹3.3t₹369.8b30x35.4x4x
Mon, 18 Sep 2023₹13.3t₹3.3t₹369.5b29.5x36.1x4.1x
Wed, 16 Aug 2023₹13.0t₹3.3t₹366.6b29.4x35.5x4x
Fri, 14 Jul 2023₹11.9t₹3.2t₹342.4b26.7x34.7x3.8x
Sun, 11 Jun 2023₹11.0t₹3.2t₹342.4b26x32.1x3.5x
Tue, 09 May 2023₹10.5t₹3.1t₹292.7b26.7x35.7x3.4x
Thu, 06 Apr 2023₹9.6t₹3.0t₹277.5b24.4x34.6x3.2x
Sat, 04 Mar 2023₹9.4t₹3.0t₹277.5b23x33.9x3.1x
Mon, 30 Jan 2023₹9.8t₹2.9t₹284.0b25.1x34.3x3.3x
Wed, 28 Dec 2022₹9.9t₹2.9t₹274.9b26.7x36x3.5x
Fri, 25 Nov 2022₹10.1t₹2.9t₹274.7b26.5x36.6x3.5x
Price to Earnings Ratio

36.6x


Total Market Cap: ₹10.1tTotal Earnings: ₹274.7bTotal Revenue: ₹2.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.8x202320242025
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 33.5x which is lower than its 3-year average PE of 36.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 30% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market1.26%
Healthcare1.01%
Pharma1.63%
Pharma1.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.76k2.5%
+₹102.5b		-1.0%PE40.4x
AUROPHARMA Aurobindo Pharma₹1.24k6.1%
+₹41.3b		-0.9%PE21x
500257 Lupin₹2.05k3.6%
+₹32.6b		0.5%PE21.6x
500124 Dr. Reddy's Laboratories₹1.24k2.7%
+₹26.8b		2.4%PE17.7x
IPCALAB Ipca Laboratories₹1.42k7.6%
+₹25.6b		-9.6%PE43.4x

Latest News

COHANCE
₹596.45
Cohance Lifesciences
7D
-13.7%
1Y
-53.4%

COHANCE: Future Leadership Transition Will Drive Renewed Momentum

Analysts have revised their price target for Cohance Lifesciences downward from ₹1,170.63 to ₹930.00. This change reflects updated expectations for lower profit margins and slightly reduced revenue growth projections.
530549
₹365.85
Shilpa Medicare
7D
-7.2%
1Y
-16.8%

530549: Successful Phase 3 Results Will Drive Stronger Outlook Ahead

Analysts have raised their price target for Shilpa Medicare to ₹514.5. This update is supported by improved growth and profitability projections, which offset a slightly higher discount rate and lower expected future P/E. What's in the News Shilpa Medicare successfully completed its fourth complex clinical program, SMLINJ011, achieving positive topline Phase 3 results for OERIS™ (Ondansetron Extended-Release Injection).
AARTIPHARM
₹712.35
Aarti Pharmalabs
7D
-7.7%
1Y
12.2%
RUBICON
₹724.40
Rubicon Research
7D
16.7%
1Y
n/a
AETHER
₹876.55
Aether Industries
7D
19.6%
1Y
5.9%

We Ran A Stock Scan For Earnings Growth And Aether Industries (NSE:AETHER) Passed With Ease

Nov 15
We Ran A Stock Scan For Earnings Growth And Aether Industries (NSE:AETHER) Passed With Ease
500257
₹2,047.15
Lupin
7D
3.6%
1Y
0.5%
IPCALAB
₹1,422.90
Ipca Laboratories
7D
7.6%
1Y
-9.6%
506943
₹1,798.50
J. B. Chemicals & Pharmaceuticals
7D
-1.5%
1Y
8.0%
500420
₹3,793.15
Torrent Pharmaceuticals
7D
-0.8%
1Y
22.6%

500420: New Settlement Agreement Will Shape U S Market Opportunity After 2030

Analysts have raised their price target for Torrent Pharmaceuticals from ₹3,929 to ₹4,010, citing slightly improved revenue growth forecasts and higher projected profit margins. What's in the News Torrent Pharmaceuticals has entered into a settlement agreement with Eisai Co., Ltd.
AJANTPHARM
₹2,458.10
Ajanta Pharma
7D
-4.6%
1Y
-16.2%
ZYDUSLIFE
₹928.40
Zydus Lifesciences
7D
-1.1%
1Y
-2.0%

Analysts Are Updating Their Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Estimates After Its Second-Quarter Results

Nov 09
Analysts Are Updating Their Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Estimates After Its Second-Quarter Results
GLAND
₹1,790.10
Gland Pharma
7D
-3.3%
1Y
0.4%

GLAND: Revenue Opportunities And Competitive Risks Will Be Balanced Going Forward

Narrative Update: Gland Pharma Price Target Revision Analysts have slightly lowered their price target for Gland Pharma from ₹1,938 to ₹1,925. This reflects modestly tempered expectations on revenue growth, profitability, and valuation multiples.
SUNPHARMA
₹1,758.80
Sun Pharmaceutical Industries
7D
2.5%
1Y
-1.0%

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt

Nov 07
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt
AUROPHARMA
₹1,239.30
Aurobindo Pharma
7D
6.1%
1Y
-0.9%
LAURUSLABS
₹1,006.90
Laurus Labs
7D
2.2%
1Y
105.9%

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.
500124
₹1,243.55
Dr. Reddy's Laboratories
7D
2.7%
1Y
2.4%

Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities

Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.